Recently, the discovery of a new murine model, LSL-Kras, showed tissue-selective neoplastic transformation to understand the tumor initiation, progression, and therapy response in KrasG12D, KrasG12C, KrasG12R, and KrasG13D mutant models [50]. This evidence concerns the gene KRAS and neoplasm.